Buparlisib (Bup) Or Placebo (Pbo) Plus Fulvestrant (Ful) In Postmenopausal Patients (Pts) With Hormone Receptor-Positive (Hr Plus ), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Advanced Breast Cancer (Abc): Overall Survival (Os) Results From Belle-2, A Randomized, Phase Iii Study